Tunable Thermal‐Sensitive Polymer–Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells

Yoon, Hyeun Joong; Shanker, Apoorv; Wang, Yan; Kozminsky, Molly; Jin, Qiao; Palanisamy, Nallasivam; Burness, Monika L.; Azizi, Ebrahim; Simeone, Diane M.; Wicha, Max S.; J, Kim; Nagrath, Sunitha

doi:10.1002/adma.201600658

Cited by 137 publications

(90 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Yoon et al developed a microfluidic chip with thermal-sensitive polymer-controlled CTC release. 47 Lv et al designed a near-infrared (NIR) light-responsive substrate for highly efficient immune-capture and biocompatible site-release of CTCs. 48 …”

Section: Ctc Detection Technologies With Enrichmentmentioning

confidence: 99%

Current detection technologies for circulating tumor cells

2017

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are cancer cells that circulate in the blood stream after being naturally shed from original or metastatic tumors, and can lead to a new fatal metastasis. CTCs have become a hotspot research field during the last decade. Detection of CTCs, as a liquid biopsy of tumors, can be used for early diagnosis of cancers, earlier evaluation of cancer recurrence and chemotherapeutic efficacy, and choice of individual sensitive anti-cancer drugs. Therefore, CTC detection is a crucial tool to fight against cancer. Herein, we classify the currently reported CTC detection technologies, introduce some representative samples for each technology, conclude the advantages and limitations, and give a future prospective including challenges and opportunities of CTC detection.

show abstract

Section: Ctc Detection Technologies With Enrichmentmentioning

confidence: 99%

Current detection technologies for circulating tumor cells

2017

View full text Add to dashboard Cite

show abstract

“…Refinements such as increasing throughputs, targeting multiple populations with the use of multiple antibodies may be the important steps needed to further improve these technologies. Use of novel materials and reversible conjugation of antibodies that may enable CTC release will offer more robust CTC analysis modules, as these CTCs can then be utilized for downstream assays . Using immuno‐capture methods, different populations of CTCs can be segregated for further analysis that may be able to identify tumorigenic CTCs, such as xenograft studies .…”

Section: The Futurementioning

confidence: 99%

Affinity Versus Label‐Free Isolation of Circulating Tumor Cells: Who Wins?

Murlidhar

Rivera-Báez

Nagrath

2016

Small

Self Cite

View full text Add to dashboard Cite

The study of circulating tumor cells (CTCs) has been made possible by many technological advances in their isolation. Their isolation has seen many fronts, but each technology brings forth a new set of challenges to overcome. Microfluidics has been a key player in the capture of CTCs and their downstream analysis, with the aim of shedding light into their clinical application in cancer and metastasis. Researchers have taken diverging paths to isolate such cells from blood, ranging from affinity-based isolation targeting surface antigens expressed on CTCs, to label-free isolation taking advantage of the size differences between CTCs and other blood cells. For both major groups, many microfluidic technologies have reported high sensitivity and specificity for capturing CTCs. However, the question remains as to the superiority among these two isolation techniques, specifically to identify different CTC populations. This review highlights the key aspects of affinity and label-free microfluidic CTC technologies, and discusses which of these two would be the highest benefactor for the study of CTCs.

show abstract

“…CTC detection in the clinical samples has been challenging. Dr. Sunitha Nagrath’s lab (University of Michigan) developed the GO-Chip made of graphene oxide and antibody-coated microposts to rapidly separate CTCs from blood samples (48). She demonstrated that 50% of patients with lung cancer were found to have CTCs in clusters, and their initial data show that these clusters correlate with survival.…”

Section: Clinical Trials Of Csc Targeting Therapeuticsmentioning

confidence: 99%

New Advances and Challenges of Targeting Cancer Stem Cells

et al. 2017

View full text Add to dashboard Cite

The second International Cancer Stem Cell Conference in Cleveland, Ohio, on September 20–23, 2016, convened 330 attendees from academic, industrial, and clinical organizations. It featured a debate on the concepts and challenges of the cancer stem cells (CSC) as well as CSC-centered scientific sessions on clinical trials, genetics and epigenetics, tumor microenvironment, immune suppression, metastasis, therapeutic resistance, and emerging novel concepts. The conference hosted 35 renowned speakers, 100 posters, 20 short talks, and a preconference workshop. The reported advances of CSC research and therapies fostered new collaborations across national and international borders, and inspired the next generation’s young scientists.

show abstract

Tunable Thermal‐Sensitive Polymer–Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor Cells

Cited by 137 publications

References 44 publications

Current detection technologies for circulating tumor cells

Current detection technologies for circulating tumor cells

Affinity Versus Label‐Free Isolation of Circulating Tumor Cells: Who Wins?

New Advances and Challenges of Targeting Cancer Stem Cells

Contact Info

Product

Resources

About